Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Redx Pharma Plc (REDX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
12.00 -0.75    -5.88%
16:35:59 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 582,013
  • Bid/Ask: 11.50 / 13.50
  • Day's Range: 11.50 - 12.70
Type:  Equity
Market:  United Kingdom
ISIN:  GB00BSNB6S51 
SEDOL:  BSNB6S5
Redx Pharma Plc 12.00 -0.75 -5.88%

LON:REDX Financials

 
This summary provides an overview of the most significant critical numbers from each of the Redx Pharma Plc financial reports, including theRedx Pharma Plc income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.

Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the LON:REDX financials over time via breakdowns of their annual reports.

Redx Pharma Plc reported earnings results for the half year ended March 31, 2023. For the half year, the company reported sales was GBP 2.31 million compared to GBP 8.35 million a year ago. Net loss was GBP 20.77 million compared to GBP 9.76 million a year ago. Basic loss per share from continuing operations was GBP 0.062 compared to GBP 0.035 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

REDX Income Statement & Profits

Gross margin TTM 100%
Operating margin TTM -737.27%
Net Profit margin TTM -789.05%
Return on Investment TTM -57.98%
 Total Revenue  Net Income
Period Ending: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022
Total Revenue 1.16 1.16 5.17 5.17
Gross Profit 1.16 1.16 5.17 5.17
Operating Income -8.81 -8.81 -4.86 -4.86
Net Income -10.38 -10.38 -4.12 -4.12

REDX Balance Sheet

Quick Ratio MRQ 0.86
Current Ratio MRQ 1.11
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 527%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022
Total Assets 42.85 42.85 62.48 62.48
Total Liabilities 27.92 27.92 29.16 29.16
Total Equity 14.93 14.93 33.32 33.32

%ENGLISH_NAME% Latest Cash Flow Statement

Cash Flow/Share TTM -0.1
Revenue/Share TTM 0.01
Operating Cash Flow  -35.48%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -9.33 -9.33 -5.53 -5.53
Cash From Investing Activities -0.082 -0.082 -0.042 -0.042
Cash From Financing Activities -0.204 -0.204 16.7 16.7
Net Change in Cash -9.62 -9.62 11.14 11.14
* In Millions of GBP (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

REDX Price Commentary

Write your thoughts about Redx Pharma Plc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Peter Ovens
Peter Ovens Feb 01, 2023 15:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A woman with deadly bile duct cancer is surviving against all the odds thanks to a new experimental drug. Carol Hardy, from Penrith, Cumbria, is taking part in a clinical trial the Christie NHS Foundation Trust in Manchester, and doctors hope the drug may eventually be used for a range of cancers. The tablets – known only as RXC004 – contain a compound that blocks a pathway known to be over-activated in bile duct cancer." THAT is another one, and RXC004 is REDX.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email